The majority of studies indicate that GLP-1 RAs are associated with an increased risk of gallbladder or biliary tract diseases (Wang et al., 2022; Woronow et al., 2022; Gameil et al., 2024; Pratley et al., 2024; Wang et al., 2024; Yang et al., 2024), such as cholecystitis and cholelithiasis (Nreu et al., 2020; Zeng et al., 2023). Here, GLP1R is linked to biliary tract disorder.